nafamostat has been researched along with Libman-Sacks Disease in 1 studies
nafamostat: inhibitor of trypsin, plasmin, pancreatic kallikrein, plasma kallikrein & thrombin; strongly inhibits esterolytic activities of C1r & C1 esterase complement-mediated hemolysis; antineoplastic
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ikehara, S | 1 |
| Shimamura, K | 1 |
| Aoyama, T | 1 |
| Fujii, S | 1 |
| Hamashima, Y | 1 |
1 other study available for nafamostat and Libman-Sacks Disease
| Article | Year |
|---|---|
Effect of FUT-175, a new synthetic protease inhibitor, on the development of lupus nephritis in (NZB x NZW) F1 mice.
Topics: Animals; Autoimmune Diseases; Benzamidines; Female; Glomerulonephritis; Guanidines; Lupus Erythemato | 1985 |